Interferon‐γ therapy for infection control in chronic granulomatous disease

Shoichi Ohga, JUN OKAMURA, HIDEKI NAKAYAMA, YOSHIHISA NAGATOSHI, KOHJI UEDA

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Interferon (IFN)‐γ was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection‐associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O 2 ‐ production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O 2 ‐ generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN‐γ may be variably beneficial for infection control in CGD‐patients, irrespective of the in vitro phagocyte functions. A longer follow‐up time is needed to confirm the IFN response in CGD‐patients. 1995 Japan Pediatric Society

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalPediatrics International
Volume37
Issue number3
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Chronic Granulomatous Disease
Infection Control
Interferons
Therapeutics
Hospitalization
Neutrophils
Nitroblue Tetrazolium
Liver Abscess
Lymphadenitis
NADPH Oxidase
Phagocytes
Communicable Diseases
Pneumonia
Japan
Pediatrics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Interferon‐γ therapy for infection control in chronic granulomatous disease. / Ohga, Shoichi; OKAMURA, JUN; NAKAYAMA, HIDEKI; NAGATOSHI, YOSHIHISA; UEDA, KOHJI.

In: Pediatrics International, Vol. 37, No. 3, 01.01.1995, p. 315-320.

Research output: Contribution to journalArticle

Ohga, S, OKAMURA, JUN, NAKAYAMA, HIDEKI, NAGATOSHI, YOSHIHISA & UEDA, KOHJI 1995, 'Interferon‐γ therapy for infection control in chronic granulomatous disease', Pediatrics International, vol. 37, no. 3, pp. 315-320. https://doi.org/10.1111/j.1442-200X.1995.tb03321.x
Ohga, Shoichi ; OKAMURA, JUN ; NAKAYAMA, HIDEKI ; NAGATOSHI, YOSHIHISA ; UEDA, KOHJI. / Interferon‐γ therapy for infection control in chronic granulomatous disease. In: Pediatrics International. 1995 ; Vol. 37, No. 3. pp. 315-320.
@article{3ae82359c2b94e90a5ba64f0c6eeac06,
title = "Interferon‐γ therapy for infection control in chronic granulomatous disease",
abstract = "Interferon (IFN)‐γ was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection‐associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O 2 ‐ production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O 2 ‐ generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN‐γ may be variably beneficial for infection control in CGD‐patients, irrespective of the in vitro phagocyte functions. A longer follow‐up time is needed to confirm the IFN response in CGD‐patients. 1995 Japan Pediatric Society",
author = "Shoichi Ohga and JUN OKAMURA and HIDEKI NAKAYAMA and YOSHIHISA NAGATOSHI and KOHJI UEDA",
year = "1995",
month = "1",
day = "1",
doi = "10.1111/j.1442-200X.1995.tb03321.x",
language = "English",
volume = "37",
pages = "315--320",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Interferon‐γ therapy for infection control in chronic granulomatous disease

AU - Ohga, Shoichi

AU - OKAMURA, JUN

AU - NAKAYAMA, HIDEKI

AU - NAGATOSHI, YOSHIHISA

AU - UEDA, KOHJI

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Interferon (IFN)‐γ was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection‐associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O 2 ‐ production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O 2 ‐ generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN‐γ may be variably beneficial for infection control in CGD‐patients, irrespective of the in vitro phagocyte functions. A longer follow‐up time is needed to confirm the IFN response in CGD‐patients. 1995 Japan Pediatric Society

AB - Interferon (IFN)‐γ was subcutaneously administered to four patients with chronic granulomatous disease (CGD) in order to evaluate its effects in controlling infection. Patients 1 to 3 were all males, while patient 4 was female. In patients 2 and 4, the length of infection‐associated hospitalization during the year of IFN therapy was significantly shorter than that during the whole observed period prior to IFN therapy. In patients 1 and 2, the length of hospitalization during a year of IFN therapy was shorter than that during 1 year prior to the therapy. Patient 3 exhibited no reduction in terms of the length of infectious disease during IFN therapy, because he suffered from a liver abscess before and during the therapy. As soon as the IFN therapy was stopped, patient 2 developed pneumonia and lymphadenitis, which were promptly relieved by readministering the agent. During 1 year of IFN therapy, patients 1, 2 and 4 showed no significant changes in either the nitroblue tetrazolium test, O 2 ‐ production or the expression of NADPH oxidase components in neutrophils. On the other hand, the O 2 ‐ generating ability of neutrophils from patient 3 slightly increased. Our limited observations suggest that IFN‐γ may be variably beneficial for infection control in CGD‐patients, irrespective of the in vitro phagocyte functions. A longer follow‐up time is needed to confirm the IFN response in CGD‐patients. 1995 Japan Pediatric Society

UR - http://www.scopus.com/inward/record.url?scp=84987014358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987014358&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.1995.tb03321.x

DO - 10.1111/j.1442-200X.1995.tb03321.x

M3 - Article

C2 - 7645379

AN - SCOPUS:84987014358

VL - 37

SP - 315

EP - 320

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 3

ER -